COVID-19 and Nursing Home Deaths: What Do We Actually Know?

By Chuck Dinerstein, MD, MBA — Apr 27, 2020
It's pretty clear by now that the statistics on COVID-19 are a hot mess. One news report quoted Betsy McCaughey, New York's former lieutenant governor, characterizing nursing homes as "death pits." Is the underlying problem something we should have known, or already measured? Or is this another healthcare disparity that we have chosen to ignore, which COVID-19 subsequently revealed? Let's take a look.

It's pretty clear by now that the statistics on COVID-19 are a hot mess. One news report quoted Betsy McCaughey, New York's former lieutenant governor, characterizing nursing homes as "death pits." Is the underlying problem something we should have known, or already measured? Or is this another healthcare disparity that we have chosen to ignore, which COVID-19 subsequently revealed? Let's take a look.

Covid-19 and Intravenous Nutrition - a Life-Saving Choice!

By Special to ACSH — Apr 24, 2020
Since Covid-19 infection carries with it a crushing immunocompromise, it is important to recognize that the most common global reason of immunodeficiency is malnutrition and that the leading causation of world morbidity/mortality is chronic malnutrition.

Since Covid-19 infection carries with it a crushing immunocompromise, it is important to recognize that the most common global reason of immunodeficiency is malnutrition and that the leading causation of world morbidity/mortality is chronic malnutrition.

If Remdesivir Really Fails There May Be No Treatment for Coronavirus

By Josh Bloom — Apr 24, 2020
It's only one trial, and we don't even know if the report is correct. But a leaked draft report indicated that remdesivir was ineffective in its first controlled trial. Let's assume that this is true and we see the same from other trials. If so, this will not simply be another experimental drug failing. It will be deeply disturbing. Here's why.

It's only one trial, and we don't even know if the report is correct. But a leaked draft report indicated that remdesivir was ineffective in its first controlled trial. Let's assume that this is true and we see the same from other trials. If so, this will not simply be another experimental drug failing. It will be deeply disturbing. Here's why.

Toxicology: Is Organic Food Safer to Eat?

By Michael Dourson — Apr 24, 2020
Are the small levels of pesticides, herbicides and genetic modifications in our food -- whether human-made or natural -- harmful? Let's put the virus aside for a moment and see what we find.

Are the small levels of pesticides, herbicides and genetic modifications in our food -- whether human-made or natural -- harmful? Let's put the virus aside for a moment and see what we find.

When Do We Mingle? The Tyranny of an 'Abundance of Caution'

By Chuck Dinerstein, MD, MBA — Apr 24, 2020
When it comes to unwinding the lockdown, we are faced with the urge to be social once again. And since we are also faced with huge uncertainty, what does "an abundance of caution" actually mean?

When it comes to unwinding the lockdown, we are faced with the urge to be social once again. And since we are also faced with huge uncertainty, what does "an abundance of caution" actually mean?

What the Apparent Failure of Remdesivir in its 1st Controlled Trial Means, and Doesn't Mean

By Josh Bloom — Apr 23, 2020
Preliminary data, obtained from a randomized clinical trial of remdesivir in China, look bad. Maybe even very bad. But this doesn't mean that the drug won't be shown to be useful in other trials. Nonetheless, not good news.

Preliminary data, obtained from a randomized clinical trial of remdesivir in China, look bad. Maybe even very bad. But this doesn't mean that the drug won't be shown to be useful in other trials. Nonetheless, not good news.

How I Became Open-Minded

By Alex Berezow, PhD — Apr 23, 2020
As is most everything in life, being open-minded is hard work. It actually takes conscientious effort. Like being charitable or becoming a violin virtuoso, it requires practice. One does not become open-minded overnight. But you can always start on your journey today.

As is most everything in life, being open-minded is hard work. It actually takes conscientious effort. Like being charitable or becoming a violin virtuoso, it requires practice. One does not become open-minded overnight. But you can always start on your journey today.

What I'm Reading (Apr. 23)

By Chuck Dinerstein, MD, MBA — Apr 23, 2020
Where does the 2600 tons of oxygen we use daily in the hospitals come from? Not all creatures have a microbiome, what is up with that? Why are lies and misinformation so resilient? And two lessons from history, one about where we shelter, the other about "travel papers."

Where does the 2600 tons of oxygen we use daily in the hospitals come from? Not all creatures have a microbiome, what is up with that? Why are lies and misinformation so resilient? And two lessons from history, one about where we shelter, the other about "travel papers."

Coronavirus and the Fallacy of the False Dilemma

By Alex Berezow, PhD — Apr 22, 2020
Should we open up the economy immediately or remain on lockdown indefinitely until a vaccine is made? Believe it or not, there are other options. It's too bad that society isn't smart enough to understand that.

Should we open up the economy immediately or remain on lockdown indefinitely until a vaccine is made? Believe it or not, there are other options. It's too bad that society isn't smart enough to understand that.

Gilead is Scaling Up Remdesivir. What Does This Tell Us?

By Josh Bloom — Apr 22, 2020
Remdesivir, the most promising anti-coronavirus drug at this time is no fun to synthesize. But Gilead, the drug's maker, is synthesizing a whole bunch of it. Does this tell us anything about whether the drug works? Maybe.

Remdesivir, the most promising anti-coronavirus drug at this time is no fun to synthesize. But Gilead, the drug's maker, is synthesizing a whole bunch of it. Does this tell us anything about whether the drug works? Maybe.